Synthetic aminoindanes: a summary of existing knowledge
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F17%3A43919035" target="_blank" >RIV/00023752:_____/17:43919035 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/17:43915969
Výsledek na webu
<a href="https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fpsyt.2017.00236" target="_blank" >10.3389/fpsyt.2017.00236</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Synthetic aminoindanes: a summary of existing knowledge
Popis výsledku v původním jazyce
Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural effects, pharmacokinetics and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindane, MDAI, 5,6-methylenedioxy-2-aminoindane, 5-IAI, 5-Iodo-2-aminoindane, 2-aminoindane, MDMAI, 5,6-Methylenedioxy-N-methyl-2-aminoindane, MMAI, 5-Methoxy-6-methyl-2-aminoindane. WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects Erowid, PsychonautWiki, Bluelight and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use as e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy, however they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin), mean that they may pose a significant risk of serotonin syndrome at high doses, or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where aminoindanes-related deaths have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.
Název v anglickém jazyce
Synthetic aminoindanes: a summary of existing knowledge
Popis výsledku anglicky
Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural effects, pharmacokinetics and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindane, MDAI, 5,6-methylenedioxy-2-aminoindane, 5-IAI, 5-Iodo-2-aminoindane, 2-aminoindane, MDMAI, 5,6-Methylenedioxy-N-methyl-2-aminoindane, MMAI, 5-Methoxy-6-methyl-2-aminoindane. WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects Erowid, PsychonautWiki, Bluelight and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use as e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy, however they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin), mean that they may pose a significant risk of serotonin syndrome at high doses, or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where aminoindanes-related deaths have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30215 - Psychiatry
Návaznosti výsledku
Projekt
<a href="/cs/project/LO1611" target="_blank" >LO1611: Udržitelnost pro Národní ústav duševního zdraví</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Frontiers in Psychiatry
ISSN
1664-0640
e-ISSN
—
Svazek periodika
8
Číslo periodika v rámci svazku
November
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
7
Strana od-do
"Article Number: 236"
Kód UT WoS článku
000415593400001
EID výsledku v databázi Scopus
2-s2.0-85034572487